Myeloma Minute: ASH 2019 Late-Breaking Abstracts


| INNOVATION | Latest Research


ASH 2019 Update: Late-Breaking Abstracts and Hot-Topic Posters

Today, the American Society of Hematology (ASH) released late-breaking abstracts to be presented in a few weeks at the organization’s 2019 annual meeting. These feature “substantive, novel, and groundbreaking data” and an important myeloma study was among them. IMF Chairman Brian G.M. Durie, MD, tells what makes this—and several other ASH myeloma studies—worth knowing about.


| INSPIRATION | #GivingTuesday


'Tis the Season for Giving!

Save the Date: #GivingTuesday is on December 3, 2019. Created in 2012, #GivingTuesday began as a simple idea: a day that encourages people to do good. Over the past seven years, this idea has grown into a global movement. The IMF will take part and is grateful to you for giving and supporting our mission!


| INSPIRATION | Fundraising


| ACTION | Advocacy Alert


Shop for Opal Jewelry and Donate to the IMF
How Short-Term Government Funding Could Impact Cancer Research

Amy Klitsner is a jewelry artist with studios in California and Hawaii. She specializes in making fine jewelry from Australian and Ethiopian opals, and colorful fused glass. Amy is passionate about raising funds for the IMF because she lost her mother to multiple myeloma. A portion of each sale will be donated to the International Myeloma Foundation. Click the button below for the full jewelry catalog.

If you have been following what has been going on in Washington D.C.lately, you have likely heard a lot about government shutdowns and continuing resolutions (CRs). Click the link below to learn more about how the current state of affairs could impact cancer research.



| ACTION | Class-Action Refunds


Deadline Approaches for Class-Action Settlement Refunds

December 30, 2019 is the deadline for qualified applicants to submit a claim for refunds for Revlimid and Thalomid co-payments resulting from Celgene Corporation’s settlement of a class-action suit in July 2019. The settlement class consists of people or entities who paid the purchase price of Thalomid or Revlimid in California, the District of Columbia, Florida, Kansas, Maine, Massachusetts, Michigan, Nebraska, New York, North Carolina, Oregon, Pennsylvania, Rhode Island or Tennessee, for consumption by themselves, their families, or their members, employees, insureds, participants or beneficiaries.


| #ASKDRDURIE | Dr. Durie's Weekly Web Video Series



Search the Myeloma Matrix 2.0

Join the conversation about myeloma on the Smart Patients Message Board

Clinical Trial Fact Sheets

OCEAN Trial (Now Accruing)

IKEMA Trial (Fully Accrued)

IMROZ Trial (Fully Accrued)

BOSTON Trial (Fully Accrued)

December 6, 2019
ASH Satellite Symposium

December 9, 2019
IMWG Conference Series: ASH 2019

January 10, 2020
Magical Miles for Myeloma
Walt Disney World - Orlando

March 13-14, 2020
IMF Patient & Family Seminar
Boca Raton, FL

subscribe_button.png          donate_button_bottom.png
We Thank Our Sponsors:
Celgene Corporation, Genentech, and Takeda Oncology

We also thank individuals like you for your continued support!

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.